Albert J. and Judith A. Dunlap Cancer Center at Mayo Clinic Health ...

cases were detected at a highly curable stage. This high percent of early stage cases is also a marker of the
clinic’s efforts to promote screening and accuracy of early detection methods such as mammography.
3. Quality of breast cancer care at Mayo Clinic Health System in Eau Claire.
We reviewed 80 consecutive cases diagnosed and treated by our group in 2010–2011. They were reviewed for
the care they received and how they matched up to recognized measures of high-quality breast cancer care. The
following summarizes this review.
A. The pattern of care in the CP3R data reports — These reports track the long-term trends in the
group’s efforts in key survival enhancing measures. These are national measures and felt by many
groups, including the ACS CoC, NCCN, ASCO and others, to demonstrate the quality of a group’s
cancer program.
Cancer Program Practice Profile Reports (CP 3 R)
for Breast Cancers Diagnosed 2004 - 2010
Mayo Clinic Health System, Eau Claire, Wis.
FACILITY SELECTION ALL MEASURES SUMMARY THIS MEASURE SUMMARY
Combination chemotherapy is considered or
administered within four months (120 days) of diagnosis
for women under 70 with AJCC T1cN0M0, or Stage II
or III hormone receptor negative breast cancer. [MAC]
Diagnosis Year: 2010
(Last Update: Dec 10, 2012 11:12:16 PM CST)
Perf. Rate 95% CI Cases #Prog.
My Cancer Program 100 % (100 - 100) 7
My State (WI) 98.2 % (96.6 - 99.8) 271 32
My ACS Division (Mid-West) 97.1 % (95.8 - 98.4) 654 69
My Census Region (Greatlakes) 92.9 % (91.9 - 93.9) 2482 253
My CoC Program Type (COMP) 91.9 % (91.3 - 92.5) 6821 560
All CoC Approved Programs (ALL) 90.7 % (90.2 - 91.2) 13670 1283
Interpreting this table: The estimated performance rates shown in this table provide your cancer program with an
indication of the proportion of women under 70 with advanced, mid-stage HR-breast cancer treated or considered for
multiagent chemotherapy according to recognized standards of care. These rates are computed based on data directly
reported from CoC approved registries to the NCDB using specifications endorsed by the NQF.
The CP3R provides cancer programs with the opportunity to examine data to determine if these performance rates are
representative of the care provided at the institution. This application provides the ability to review and modify cases
using this application. Simply click on the cell of underlined cases of interest to view a detailed case listing.
Displayed performance rates are immediately updated once modifications via the CP3R are completed by cancer
program staff. Note, any modifications made online should be reflected at the local cancer registry, and cancer
programs are encouraged to resubmit data to the NCDB.